AdvisorShares Psychedelics ETF, which is adding Mindset Pharma and lists Cybin as a top holding, looks like a good trip.
However, traders will need to show a lot of patience if they buy shares of the biopharmaceutical company.
Here's how traders can play the stock.
In a market with elevated valuations and low yields, we see pharmaceutical stocks as a respite from both.
It's time to turn to the chart to determine whether the pullback is an opportunity to buy or if it is something more.
Here's where it might be headed.
But the worst appears to be behind them.
Plus, Zscaler largely delivers for its owners with its latest results.
The charts and indicators tell us the correction is over.
BP, Novartis and British American Tobacco offer healthy payouts that look secure for years to come.